Search strategy and evidence selection

Search strategy and evidence selection

Search strategy

For the clinical evidence

Embase 1980 to 2015 Week 11, Ovid MEDLINE(R) In‑Process & Other Non‑Indexed Citations and Ovid MEDLINE(R) 1946 to Present; searched 10 March 2015.

1. tearlab.mp. [mp=ti, ab, sh, hw, tn, ot, dm, mf, dv, kw, nm, kf, px, rx, an, ui]

2. osmometer.mp. [mp=ti, ab, sh, hw, tn, ot, dm, mf, dv, kw, nm, kf, px, rx, an, ui]

3. osmolarity.mp. [mp=ti, ab, sh, hw, tn, ot, dm, mf, dv, kw, nm, kf, px, rx, an, ui]

4. Osmolarity testing.mp. [mp=ti, ab, sh, hw, tn, ot, dm, mf, dv, kw, nm, kf, px, rx, an, ui]

5. meibomian gland dysfunction.mp. or Dry Eye Syndromes/

6. dry eye disease.mp. [mp=ti, ab, sh, hw, tn, ot, dm, mf, dv, kw, nm, kf, px, rx, an, ui]

7. Evaporative dry eye.mp. [mp=ti, ab, sh, hw, tn, ot, dm, mf, dv, kw, nm, kf, px, rx, an, ui]

8. dry eye disease severity.mp. [mp=ti, ab, sh, hw, tn, ot, dm, mf, dv, kw, nm, kf, px, rx, an, ui]

9. 1 or 2 or 3 or 4

10. 5 or 6 or 7 or 8

11. 9 and 10

12. limit 11 to english language

13. limit 12 to yr="2005 ‑ Current"

For the health economics evidence

Embase 1974 to 2015 July 02, Ovid MEDLINE(R) In‑Process & Other Non‑Indexed Citations and Ovid MEDLINE(R) 1946 to Present; searched on 03 July 2015

1. tearlab.mp.

2. osmometer.mp.

3. osmolarity.mp.

4. Osmolarity testing.mp.

5. 1 or 2 or 3 or 4

6. meibomian gland dysfunction.mp. or Dry Eye Syndromes/

7. Dry Eye Disease.mp.

8. Evaporative Dry Eye.mp.

9. dry eye disease severity.mp.

10. 6 or 7 or 8 or 9

11. cost$.mp.

12. economic$.mp.

13. 11 or 12

14. 5 and 10 and 13

15. limit 14 to english language

16. limit 15 to yr="2005 ‑ Current"

Cochrane Database of Systematic Reviews: Issue 7 of 12, July 2015

Cochrane Central Register of Controlled Trials: Issue 6 of 12, June 2015

Database of Abstracts of Reviews of Effect: Issue 2 of 4, April 2015

Health Technology Assessment Database: Issue 2 of 4, April 2015

NHS Economic Evaluation Database: Issue 2 of 4, April 2015

#1 Tearlab

#2 Osmolarity testing

#3 #1 or #2

#4 Meibomian gland dysfunction

#5 Dry Eye Syndromes

#6 Dry Eye Disease

#7 #4 or #5 or #6

#8 cost$

#9 economic$

#10 #8 or #9

#11 #3 and #7 and #10

Evidence selection

For the clinical evidence

  • Total number of publications reviewed: 38

  • Total number of publications considered relevant: 17

  • Total number of publications selected for inclusion in this briefing: 6.

For the health economics evidence

  • Total abstracts: 6

  • Duplicates: 0

  • Abstracts reviewed: 6

  • Full papers reviewed: 0.

Exclusion criteria: case studies, editorials, letters, reviews, conference proceedings/abstracts, animal studies, non‑English language studies, not using the Tearlab system.

Studies for review: 0